# US 2021/0275624 A1 · Treatments for improving or lessening impairment of mitochondrial function > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2021/0275624 A1 - Document ID: US20210275624A1 - Status: Published application - Kind: A1 - Application number: 17/193,832 - Filed: 2021-03-05 - Published: 2021-09-09 - Earliest claimed: 2020-03-06 - Assignees: Allegro Pharmaceuticals, LLC - Applicants: Allegro Pharmaceuticals, LLC - Inventors: Hampar L. Karageozian; John Y Park; Vicken H. Karageozian - Web page: https://patentgrep.com/patent/US20210275624A1 ## CPC - A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)} - A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure - A61P 39/06: Free radical scavengers or antioxidants - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Peptide therapies to improve, or lessen impairment of, mitochondrial function. These therapies are useable to disorders causing, caused by, contributing to, or related to mitochondrial dysfunction, such as neurodegeneration, metabolic disease, congestive heart failure, chronic heart failure with reduced ejection fraction, chronic heart failure with preserved ejection fraction, Barth syndrome, kidney disease and kidney failure due to percutaneous renal angiography for renal artery stenosis, impaired skeletal muscle function in the elderly, primary muscle mitochondrial myopathy and neuropathy, ischemia-reperfusion injury and protozoal infections, peripheral neuropathy, dermatologic disorders and inflamed hemorrhoids. ## Claims ### Claim 1 A method for improving mitochondrial bioenergetics in a human or animal subject in need thereof, said method comprising the step of administering to the subject a therapeutically effective amount of a peptide which causes an improvement in mitochondrial bioenergetics. ### Claim 2 (depends on 1) A method according to claim 1 wherein the subject suffers from a disorder which causes or is caused by impairment of mitochondrial bioenergetics and wherein the administration of the peptide reverses or prevents at least some of the impairment of mitochondrial bioenergetics causing or caused by said disorder. ### Claim 3 (depends on 2) A method according to claim 2 wherein the disorder comprises or results from a chemotoxic, hypoxic or ischemic insult. ### Claim 4 (depends on 2) A method according to claim 2 wherein the disorder comprises or results from metabolic stress. ### Claim 5 (depends on 2) A method according to claim 2 wherein the disorder comprises heart failure, kidney failure and kidney disease. ### Claim 6 (depends on 2) A method according to claim 2 wherein the disorder comprises a neurodegenerative disease. ### Claim 7 (depends on 6) A method according to claim 6 wherein the neurodegerative disease is selected from: Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and other disorders which cause progressive degeneration of function and/or structure of neurons of the central nervous system (CNS). ### Claim 8 (depends on 2) A method according to claim 2 wherein the disorder comprises a dermatologic disorder. ### Claim 9 (depends on 8) A method according to claim 8 wherein the dermatologic causes or is accompanied by a rash, pigmentation abnormality or acrocyanosis ### Claim 10 (depends on 8) A method according to claim 8 wherein the dermatologic disorder comprises: pruritis, atopic dermatitis or psoriasis. ### Claim 11 (depends on 2) A method according to claim 2 wherein the disorder comprises a peripheral neuropathy or peripheral nerve pain. ### Claim 12 (depends on 11) A method according to claim 11 wherein the peripheral neuropathy or peripheral nerve pain is causes or is caused by: mitochondrial dysfunction, diabetes, abnormal glucose metabolism, oxidative stress or chemotherapy. ### Claim 13 (depends on 2) A method according to claim 2 wherein the disorder comprises heart failure or reduced cardiac output. ### Claim 14 (depends on 1) A method according to claim 1 wherein the peptide comprises Risuteganib. ### Claim 15 (depends on 1) A method according to claim 1 wherein the peptide comprises a linear or cyclic form of Glycinyl-Arginyl-Glycinyl-Cysteic (acid)-Threonyl-Proline-COOH ### Claim 16 (depends on 1) A method according to claim 1 wherein the peptide has the formula: X1-Arg-Gly-Cysteic Acid-X wherein X and X1 are selected from: Phe-Val-Ala, -Phe-Leu-Ala, -Phe-Val-Gly, -Phe-Leu-Gly, -Phe-Pro-Gly, -Phe-Pro-Ala, -Phe-Val; or from Arg, Gly, Cysteic acid, Phe, Val, Ala, Leu, Pro, Thr and salts, and any combinations of any D-isomers and L-isomers thereof. ### Claim 17 (depends on 1) A method according to claim 1 wherein the peptide has the general formula: Y—X—Z wherein: Y═R, H, K, Cys(acid), G or D; X=G, A, Cys(acid), R, G, D or E; and Z=Cys(acid), G, C, R, D, N or E. ### Claim 18 (depends on 1) A method according to claim 1 wherein the peptide comprises or consists of an amino acid sequence selected from: R-G-Cys(Acid), R—R-Cys, R-CysAcid)-G, Cys(Acid)-R-G, Cys(Acid)-G-R, R-G-D, R-G-Cys(Acid). H-G-Cys(Acid), R-G-N, D-G-R, R-D-G, R-A-E, K-G-D, R-G-Cys(Acid)-G-G-G-D-G, Cyclo-{R-G-Cys(acid)-F—N-Me-V}, R-A-Cys (Acid), R-G-C, K-G-D, Cys(acid)-R-G, Cys(Acid)-G-R, Cyclo-{R-G-D-D-F—NMe-V}, H-G-Cys(acid) and salts thereof. ### Claim 19 (canceled) ### Claim 20 (depends on 1) A method according to claim 1 wherein the peptide comprises Risuteganib and wherein the subject suffers from a disorder selected from: a chemotoxic, hypoxic or ischemic insult, metabolic stress, heart failure, chronic heart failure with reduced ejection fraction, chronic heart failure with preserved ejection fraction, Barth syndrome, kidney disease, kidney failure due to percutaneous renal angiography for renal artery stenosis, impaired skeletal muscle function, primary muscle mitochondrial myopathy or neuropathy, ischemia-reperfusion injury, protozoal infections, peripheral neuropathy, dermatologic disorders, neuronerative disease, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), another disorder which causes progressive degeneration of function and/or structure of neurons of the central nervous system (CNS), a dermatologic disorder, a rash, pigmentation abnormality or acrocyanosis, pruritis, atopic dermatitis, psoriasis, a peripheral neuropathy, peripheral nerve pain, or nerve pain that causes, contributes to, or is caused by mitochondrial dysfunction, diabetes, abnormal glucose metabolism, oxidative stress or chemotherapy, heart failure or reduced cardiac output.